| Title |
Management of Genetic Syndromes Predisposing to Gynecologic Cancers
|
|---|---|
| Published in |
Current Treatment Options in Oncology, January 2013
|
| DOI | 10.1007/s11864-012-0215-3 |
| Pubmed ID | |
| Authors |
Susan Miesfeldt, Amanda Lamb, Christine Duarte |
| Abstract |
Women with personal and family histories consistent with gynecologic cancer-associated hereditary cancer susceptibility disorders should be referred for genetic risk assessment and counseling. Genetic counseling facilitates informed medical decision making regarding genetic testing, screening, and treatment, including chemoprevention and risk-reducing surgery. Because of limitations of ovarian cancer screening, hereditary breast and ovarian cancer-affected women are offered risk-reducing bilateral salpingo-oophorectomy (BSO) between ages 35 and 40 years, or when childbearing is complete. Women with documented Lynch syndrome, associated with mutations in mismatch repair genes, should be screened at a young age and provided prevention options, including consideration of risk-reducing total abdominal hysterectomy and BSO, as well as intensive gastrointestinal screening. Clinicians caring for high-risk women must consider the potential adverse ethical, legal, and social issues associated with hereditary cancer risk assessment and testing. Additionally, at-risk family members should be alerted to their cancer risks, as well as the availability of risk assessment, counseling, and treatment services. |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 59 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 17% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Doctoral Student | 5 | 8% |
| Researcher | 5 | 8% |
| Student > Master | 5 | 8% |
| Other | 9 | 15% |
| Unknown | 19 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 34% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Agricultural and Biological Sciences | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Psychology | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 22 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2013.
All research outputs
#20,178,948
of 22,693,205 outputs
Outputs from Current Treatment Options in Oncology
#548
of 654 outputs
Outputs of similar age
#250,119
of 282,503 outputs
Outputs of similar age from Current Treatment Options in Oncology
#6
of 6 outputs
Altmetric has tracked 22,693,205 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 654 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.